Disability News and Research

RSS

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death.

6 Jul 2012

PHF21A gene plays a big role in Potocki-Shaffer syndrome

A gene whose mutation results in malformed faces and skulls as well as mental retardation has been found by scientists.

6 Jul 2012

Fingolimod offers minor added benefit for patients with RRMS

The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed whether fingolimod offers an added benefit compared with the present standard therapy.

6 Jul 2012

Tips to help keep safe while celebrating Independence Day

As the Fourth of July approaches, emergency departments across the country are already beginning to treat patients injured by fireworks. According to the Consumer Product Safety Commission, hand and finger damage are the most common injuries caused by fireworks and account for 32 percent of all injuries reported.

4 Jul 2012

Signs that a child is seriously ill: Interview with Professor Middleton

There are several signs that indicate that a child is seriously ill. These can be spotted by parents, teachers and carers as well as by me or any other doctor or nurse.

4 Jul 2012

Students with 'observable' disabilities more likely to bully, be bullied in school

Students receiving special-education services for behavioral disorders and those with more obvious disabilities are more likely to be bullied than their general-education counterparts - and are also more likely to bully other students, a new study shows.

3 Jul 2012

Savient's KRYSTEXXA improves HRQOL and physical function in patients with RCG

Savient Pharmaceuticals, Inc. announced a new publication showing that adult patients with refractory chronic gout (RCG) treated bi-weekly with KRYSTEXXA- (pegloticase) experienced statistically significant and clinically meaningful improvements in health-related quality of life (HRQOL), pain and physical function.

3 Jul 2012

Current diagnosis and treatment approaches for rheumatoid arthritis

In the realm of deadly and disabling diseases, conditions such as cancer and Alzheimer's seem to attract the most media attention. But there are others that take a similarly high toll, and rheumatoid arthritis is one of them, Mayo Clinic researchers say. It is a common cause of disability: 1 of every 5 rheumatoid arthritis patients is unable to work two years after diagnosis, and within five years, that rises to one-third. Life expectancy drops by up to five years.

2 Jul 2012

Blindsight in monkeys is available in everyday environments

The visual information from eyes is sent into the brain unconsciously even if you are not aware. One of examples of unconscious seeing is a phenomenon of "blindsight" [Subjects have no awareness, but their brains can see] in subjects with visual impairment, caused by the damage of a part of the brain called the visual cortex.

29 Jun 2012

Sinai Hospital begins to use Solitaire FR device for treatment of acute stroke

Sinai Hospital has begun use of a new device that provides timely live-saving treatment for acute stroke patients. The Solitaire FR revascularization device is designed to minimize damage caused by blockage of an artery to the brain by mechanically removing blood clots and restoring blood flow.

29 Jun 2012

Senior citizens report fewer visual impairment problems than their counterparts

Today's senior citizens are reporting fewer visual impairment problems than their counterparts from a generation ago, according to a new Northwestern Medicine study. Improved techniques for cataract surgery and a reduction in the prevalence of macular degeneration may be the driving forces behind this change, the researchers said.

29 Jun 2012

CAPABLE program can help countless older adults avoid nursing home stays

Nursing homes do not have to be inevitable destinations for frail older adults. Many—even those with long-term health problems—can remain at home and be independent. All it takes is a little help to change "disability" to "capability".

28 Jun 2012

Study suggests important role for psychotherapy in rheumatoid arthritis

A study that is published in the current issue of Psychotherapy and Psychosomatics suggests an important role for psychotherapy in a severe and debilitating disease, rheumatoid arthritis.

27 Jun 2012

Positive results from Antares Pharma's VIBEX MTX human factors usability study for RA

Antares Pharma, Inc. today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis (RA).

26 Jun 2012

Clinical trial to examine functional benefits of combined therapy against stroke

Researchers at Vanderbilt University Medical Center are leading an international clinical trial to examine the functional benefits of a combined therapy to treat acute ischemic stroke, a type of stroke where a blood clot becomes lodged in an artery within the brain, reducing blood flow and depriving brain cells of oxygen. Eighty-seven percent of strokes are ischemic.

26 Jun 2012

Feinstein Institute to train clinicians on how to better care for patients with schizophrenia

The Zucker Hillside Hospital campus of the Feinstein Institute for Medical Research has been approved for a $9.3+ million federal grant to train clinicians on how to better care for patients with schizophrenia.

26 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Inexpensive exome sequencing can quickly detect heterogeneous diseases

The first report of the diagnostic use of the technique of exome sequencing, where short sequences of DNA are analysed, shows that it can give good results at low cost, a researcher from The Netherlands will tell the annual conference of the European Society of Human Genetics.

25 Jun 2012

$Hip fracture type may determine regional anesthesia benefits$

Hip fracture type may determine regional anesthesia benefits

Use of regional anesthesia may reduce the risk for mortality and pulmonary complications among patients undergoing surgery for hip fracture, research shows.

22 Jun 2012

Parents must be considered during expansion of genetic screening programs for newborns

Parents must be considered when states decide to expand genetic screening programs for newborns, according to a new study that looked at mandatory testing panels and political pressure by advocacy groups.

22 Jun 2012